.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
DAPA-CKD randomized patients with chronic kidney disease and albuminuria to dapagliflozin or placebo, including many participants without diabetes. Dapagliflozin reduced the risk of sustained decline in kidney function, kidney failure or cardiovascular death and reduced the overall renal composite endpoint. The trial demonstrated that the kidney benefits of SGLT2 inhibition extend beyond glucose lowering. For internists, this is important because CKD may be present in patients who do not have diabetes yet remain at substantial renal and cardiovascular risk. Albuminuria should be measured routinely because it helps define both prognosis and eligibility for disease-modifying treatment. Dapagliflozin should be considered within an integrated CKD pathway alongside blood-pressure control, renin–angiotensin system blockade, sodium management and treatment of cardiovascular risk. The study also illustrates the value of enrolling patients according to kidney phenotype rather than a single underlying disease, a principle increasingly reflected in modern cardiorenal medicine.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
DAPA-CKD randomized patients with chronic kidney disease and albuminuria to dapagliflozin or placebo, including many participants without diabetes. Dapagliflozin reduced the risk of sustained decline in kidney function, kidney failure or cardiovascular death and reduced the overall renal composite endpoint. The trial demonstrated that the kidney benefits of SGLT2 inhibition extend beyond glucose lowering. For internists, this is important because CKD may be present in patients who do not have diabetes yet remain at substantial renal and cardiovascular risk. Albuminuria should be measured routinely because it helps define both prognosis and eligibility for disease-modifying treatment. Dapagliflozin should be considered within an integrated CKD pathway alongside blood-pressure control, renin–angiotensin system blockade, sodium management and treatment of cardiovascular risk. The study also illustrates the value of enrolling patients according to kidney phenotype rather than a single underlying disease, a principle increasingly reflected in modern cardiorenal medicine.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
